ImmuCell

ImmuCell Financing Cash Flow

The Net Financing Cash Flow of ImmuCell (ICCC) as of Oct 31, 2026 is -1.21 M USD. In the previous year, Net Financing Cash Flow was 2.88 M USD — a change of -142.06% (lower).

Financing Cash Flow

-1.21 MUSD

YoY

-142.06%

Last updated:

Net Financing Cash Flow of ImmuCell is 2025 -1.21 M USD. Net Financing Cash Flow of ImmuCell was 2024 2.88 M USD. It decreases by -142.06% lower compared to the previous year.

The ImmuCell Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2018
889,615.00 USD
Jan 1, 2019
6.94 M USD
Jan 1, 2020
1.91 M USD
Jan 1, 2021
3.88 M USD
Jan 1, 2022
1.11 M USD
Jan 1, 2023
1.75 M USD
Jan 1, 2024
2.88 M USD
Jan 1, 2025
-1.21 M USD
The ImmuCell Financing Cash Flow history
YEARFinancing Cash FlowYoY
-1.21 MUSD-142.06%
2.88 MUSD+64.60%
1.75 MUSD+57.19%
1.11 MUSD-71.27%
3.88 MUSD+102.97%
1.91 MUSD-72.47%
6.94 MUSD+680.35%
889,615.00USD-90.87%
9.75 MUSD+17.09%
8.32 MUSD+240.84%
2.44 MUSD-1,404.77%
-187,163.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Net Financing Cash Flow of ImmuCell is -1.21 M USD in 2025.

Net Financing Cash Flow of ImmuCell changed from 2.88 M USD to -1.21 M USD, representing a -142.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow ImmuCell since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's ImmuCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ImmuCell

All Key Metrics — ImmuCell